Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (BDX) will host an audio webcast on November 5, 2026, to discuss its fourth-quarter and full-year fiscal 2026 financial results.
The webcast begins at 8 a.m. ET and will include an operations and strategy update. The fiscal year ended September 30, 2026. BD will release financial information and presentation materials before the call on its investor relations website, where a replay will also be available.
BD (NYSE: BDX) joined the Global Surgery Foundation and Business Council for International Understanding to convene a maternal-safety panel on September 24.
Held at the Japan Society alongside the 81st United Nations General Assembly, the discussion explored continuous noninvasive blood pressure monitoring and other measures of blood circulation to help clinicians recognize childbirth complications earlier. Participants called for broader adoption of evidence-based maternal care and improved monitoring standards. The discussion addressed progress toward the UN goal of fewer than 70 maternal deaths per 100,000 live births by 2030.
BD (NYSE: BDX) announced nine-month AGILITY trial results showing its Revello Vascular Covered Stent met the primary endpoint in iliac artery disease.
The cohort enrolled 120 patients at 28 sites. The combined safety and effectiveness endpoint had a 2.8% failure rate, significantly below the prespecified 19% performance goal. Primary patency, meaning treated arteries remained open, was 97.2%; freedom from clinically driven repeat treatment of the target lesion was 98.3%. There were no device- or procedure-related deaths, target limb major amputations or unanticipated serious adverse device effects. Mean Rutherford disease-severity category improved from 3.0 to 0.3, and the mean walking impairment questionnaire score rose 31.7 points from baseline.
Follow-up continues through 36 months. Enrollment in a separate leg-artery cohort finished in August. Revello is CE marked but remains limited to investigational use in the United States.
BD (BDX) marked 65 years of manufacturing at its Canaan, Connecticut, facility, which produces more than 2 billion syringes annually.
The site opened in 1961 with eight employees in a 25,000-square-foot building producing about 10 million syringes a year. Today, more than 500 employees work at the 385,000-square-foot facility. BD has invested more than $34 million over the past five years to expand production capacity, modernize operations and support future growth, including three new syringe manufacturing lines and equipment upgrades.
As part of the celebration, BD will announce a $10,000 grant to the Community Health & Wellness Center. The grant brings its support since 2024 to $90,000, helping fund nutrition programs, emergency assistance and patient transportation.
BD (BDX) has appointed Ferass Abuzaina worldwide president of its Surgery business unit, effective immediately, to oversee its global performance. His responsibilities cover strategy, operations and commercial performance. He will be based at Surgery's headquarters in Warwick, Rhode Island, and report to Peter Menziuso, executive vice president and president of the Interventional segment.
Abuzaina currently serves as worldwide vice president and general manager of Advanced Repair and Reconstruction within Surgery. He joined BD in 2013 and has held leadership roles across multiple businesses, with experience in research and development, strategy and business development.
BD (BDX) announced a partnership with the U.S. Government to expand domestic manufacturing and production of essential medical consumables. BD intends to invest $19 billion in the U.S. over several years, including capital, operational and supply chain investments. Of that amount, $3 billion is intended for U.S. manufacturing expansion.
BD plans to expand end-to-end U.S. production by approximately 5 billion consumables annually, raising its domestically supplied share to roughly 80 percent, and manufacture 100 percent of its needles used in America domestically using American-made steel. The agreement provides relief from future Section 232 tariffs on covered products and inputs, subject to the final scope and implementation of those actions and achievement of agreed milestones. Final tariff rates, product scope and timing remain undetermined; BD is not currently quantifying the financial impact.
BD (BDX) marked 70 years of manufacturing at its Sandy, Utah, facility, which produces peripheral intravenous catheters.
Founded in 1956 as Deseret Pharmaceuticals, the 650,000-square-foot site employs more than 1,000 people. It makes hundreds of millions of catheters and billions of molded components each year. BD has invested more than $100 million there over the past five years to expand production capacity, modernize operations and support future innovation.
BD employs more than 1,500 people across Utah, including at a Salt Lake City business site. BD Utah inventors received 165 patents in 2025. As part of the anniversary celebration, BD plans to announce a $10,000 grant to the Maliheh Free Clinic, which provides free healthcare to uninsured and underserved people in Utah.
BD (BDX) has appointed Arthur (Art) Hu as executive vice president and chief information and digital officer, effective September 30, 2026.
Hu brings more than 25 years of experience in global technology, digital and business transformation, most recently serving as senior vice president, global chief information officer and chief technology and delivery officer for Lenovo Group’s Solutions and Services Group. His responsibilities there included leading digital technology, AI adoption and business transformation across customer, partner and employee-facing platforms. Earlier in his career, he spent over a decade at McKinsey & Company advising organizations on technology, operations, strategy and organizational transformation. Hu will succeed Denise Russell Fleming, who will retire from BD at the end of 2026.
BD (BDX) announced that Fairview Health Services is the first U.S. health system to deploy the BD Vmax 160, an intelligent pharmacy automation robot designed for high-volume, centralized outpatient pharmacy operations.
Fairview, which fills about 20,000 prescriptions per week across 25 outpatient pharmacies and mail-order services, is using BD Vmax 160 to help manage growing demand for specialty therapies, biologics, GLP-1s and refrigerated medicines. The system introduces high-speed unit-of-use automation for boxed medications, with features such as automated inventory replenishment via BD EasyLoad at a 3-second-per-tote loading time and 99.8% accuracy, automated labeling compliant with all 50 states, cold-chain capability for 2–8°C storage, and smart expiry detection that blocks expired medications from dispensing.
BD (NYSE: BDX) reported that its STANCE clinical trial of GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture has surpassed a key enrollment milestone. The study has treated 274 patients across 33 active U.S. sites, triggering the first planned interim analysis. This exceeds 50% of the trial’s maximum planned enrollment, which under the adaptive design is expected to range from 250 to 530 patients.
The prospective, randomized, controlled, multi-center trial compares GalaFLEX LITE™ Scaffold plus implant revision against conventional revision surgery without a matrix or ADM, using a 2:1 randomization. According to BD, STANCE is intended to generate safety and efficacy data to support a potential new breast indication and a future FDA Premarket Approval application for GalaFLEX LITE™ Scaffold, which is based on BD’s poly-4-hydroxybutyrate (P4HB) bioabsorbable soft tissue support platform.